{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:44:41Z","timestamp":1794271481316,"version":"4.9.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI155007"],"award-info":[{"award-number":["R01AI155007"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI139288"],"award-info":[{"award-number":["R01AI139288"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65456-x","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:57:59Z","timestamp":1764079079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV\/HIV protection"],"prefix":"10.1038","volume":"16","author":[{"given":"Jae Yeon","family":"Joo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-8400","authenticated-orcid":false,"given":"Peng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-5523","authenticated-orcid":false,"given":"Susan P.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-5923","authenticated-orcid":false,"given":"Daryll","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3348-9933","authenticated-orcid":false,"given":"Loren E.","family":"Sasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-6556","authenticated-orcid":false,"given":"Deepanwita","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-4098","authenticated-orcid":false,"given":"Jaehyeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zurla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-2008","authenticated-orcid":false,"given":"Francois","family":"Villinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-0339","authenticated-orcid":false,"given":"Philip J.","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"65456_CR1","unstructured":"Global HIV & AIDS statistics \u2014 Fact sheet. https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"65456_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399\u2013410 (2012).","journal-title":"N. Engl. J. Med."},{"key":"65456_CR3","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587\u20132599 (2010).","journal-title":"N. Engl. J. Med."},{"key":"65456_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16382-4","volume":"23","author":"BG Rogers","year":"2023","unstructured":"Rogers, B. G. et al. Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States. BMC Public Health 23, 1643 (2023).","journal-title":"BMC Public Health"},{"key":"65456_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1128\/AAC.00597-11","volume":"56","author":"J Nuttall","year":"2012","unstructured":"Nuttall, J. et al. Pharmacokinetics of Tenofovir following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques. Antimicrob. Agents Chemother. 56, 103\u2013109 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"65456_CR6","doi-asserted-by":"publisher","DOI":"10.1590\/s1678-9946202264010","volume":"64","author":"CEA Fioroti","year":"2022","unstructured":"Fioroti, C. E. A. et al. Tenofovir-induced renal and bone toxicity: report of two cases and literature review. Rev. Inst. Med. Trop. Sao Paulo 64, e10 (2022).","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"65456_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","volume":"223","author":"S Mahomed","year":"2020","unstructured":"Mahomed, S., Garrett, N., Baxter, C., Abdool Karim, Q. & Abdool Karim, S. S. Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review. J. Infect. Dis. 223, 370\u2013380 (2020).","journal-title":"J. Infect. Dis."},{"key":"65456_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288\u20131296 (2022).","journal-title":"Nat. Med."},{"key":"65456_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006313","volume":"13","author":"OF Brandenberg","year":"2017","unstructured":"Brandenberg, O. F. et al. Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. PLoS Pathog. 13, e1006313 (2017).","journal-title":"PLoS Pathog."},{"key":"65456_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/ANTI.S64762","volume":"6","author":"C Murphy","year":"2016","unstructured":"Murphy, C., Devine, T. & O\u2019Kennedy, R. Technology advancements in antibody purification. Antib. Technol. J. 6, 17\u201332 (2016).","journal-title":"Antib. Technol. J."},{"key":"65456_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","volume":"21","author":"EMJ van Brummelen","year":"2016","unstructured":"van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H. & Schellens, J. H. M. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist 21, 1260\u20131268 (2016).","journal-title":"Oncologist"},{"key":"65456_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116153","volume":"9","author":"GC Morris","year":"2014","unstructured":"Morris, G. C. et al. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. PLoS ONE 9, e116153 (2014).","journal-title":"PLoS ONE"},{"key":"65456_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00710-4","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 1\u201335 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"65456_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192\u20131204 (2024).","journal-title":"Lancet"},{"key":"65456_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1804-8","volume":"17","author":"L Van Hoecke","year":"2019","unstructured":"Van Hoecke, L. & Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 17, 54 (2019).","journal-title":"J. Transl. Med."},{"key":"65456_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/vaccines9020108","volume":"9","author":"CE Deal","year":"2021","unstructured":"Deal, C. E., Carfi, A. & Plante, O. J. Advancements in mRNA encoded antibodies for passive immunotherapy. Vaccines 9, 108 (2021).","journal-title":"Vaccines"},{"key":"65456_CR17","doi-asserted-by":"crossref","unstructured":"Alameh, M.-G. & Weissman, D. Chapter 7 - Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens. In RNA Therapeutics (eds Giangrande, P. H., de Franciscis, V. & Rossi, J. J) 141\u2013169 (Academic Press, 2022).","DOI":"10.1016\/B978-0-12-821595-1.00014-2"},{"key":"65456_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12272-022-01381-7","volume":"45","author":"S Kwon","year":"2022","unstructured":"Kwon, S., Kwon, M., Im, S., Lee, K. & Lee, H. mRNA vaccines: the most recent clinical applications of synthetic mRNA. Arch. Pharm. Res. 45, 245\u2013262 (2022).","journal-title":"Arch. Pharm. Res."},{"key":"65456_CR19","unstructured":"Salatin, S. et al. Chapter 1 - Introduction: an overview of the non-parenteral delivery of nanomedicine. In Theory and Applications of Nonparenteral Nanomedicines (eds Kesharwani, P., Taurin, S. & Greish, K.) 1\u201325 (Academic Press, 2021)."},{"key":"65456_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.addr.2021.04.009","volume":"174","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Vaginal drug delivery approaches for localized management of cervical cancer. Adv. Drug Deliv. Rev. 174, 114\u2013126 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"65456_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ymthe.2020.01.002","volume":"28","author":"KE Lindsay","year":"2020","unstructured":"Lindsay, K. E. et al. Aerosol delivery of synthetic mRNA to vaginal mucosa leads to durable expression of broadly neutralizing antibodies against HIV. Mol. Ther. J. Am. Soc. Gene Ther. 28, 805\u2013819 (2020).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"65456_CR22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.15252\/emmm.201707678","volume":"9","author":"M Thran","year":"2017","unstructured":"Thran, M. et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol. Med. 9, 1434\u20131447 (2017).","journal-title":"EMBO Mol. Med."},{"key":"65456_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","volume":"27","author":"Y Rybakova","year":"2019","unstructured":"Rybakova, Y. et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Mol. Ther. 27, 1415\u20131423 (2019).","journal-title":"Mol. Ther."},{"key":"65456_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06508-3","volume":"9","author":"PM Tiwari","year":"2018","unstructured":"Tiwari, P. M. et al. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat. Commun. 9, 3999 (2018).","journal-title":"Nat. Commun."},{"key":"65456_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).","journal-title":"Nat. Commun."},{"key":"65456_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jmb.2014.11.017","volume":"427","author":"JT Koerber","year":"2015","unstructured":"Koerber, J. T., Hornsby, M. J. & Wells, J. A. An improved single-chain fab platform for efficient display and recombinant expression. J. Mol. Biol. 427, 576\u2013586 (2015).","journal-title":"J. Mol. Biol."},{"key":"65456_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","volume":"477","author":"LM Walker","year":"2011","unstructured":"Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466\u2013470 (2011).","journal-title":"Nature"},{"key":"65456_CR28","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","volume":"6","author":"MR Gaudinski","year":"2019","unstructured":"Gaudinski, M. R. et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV 6, e667\u2013e679 (2019).","journal-title":"Lancet HIV"},{"key":"65456_CR29","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","volume":"88","author":"RS Rudicell","year":"2014","unstructured":"Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669\u201312682 (2014).","journal-title":"J. Virol."},{"key":"65456_CR30","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"65456_CR31","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1128\/JVI.03246-15","volume":"90","author":"YD Kwon","year":"2016","unstructured":"Kwon, Y. D. et al. Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design. J. Virol. 90, 5899\u20135914 (2016).","journal-title":"J. Virol."},{"key":"65456_CR32","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","volume":"165","author":"Y Huang","year":"2016","unstructured":"Huang, Y. et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165, 1621\u20131631 (2016).","journal-title":"Cell"},{"key":"65456_CR33","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","volume":"149","author":"LC Burkly","year":"1992","unstructured":"Burkly, L. C. et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149, 1779\u20131787 (1992).","journal-title":"J. Immunol."},{"key":"65456_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","volume":"90","author":"NA Doria-Rose","year":"2016","unstructured":"Doria-Rose, N. A. et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 90, 76\u201391 (2016).","journal-title":"J. Virol."},{"key":"65456_CR35","doi-asserted-by":"publisher","first-page":"17624","DOI":"10.1073\/pnas.1415789111","volume":"111","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111, 17624\u201317629 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65456_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03632-y","volume":"9","author":"CO Barnes","year":"2018","unstructured":"Barnes, C. O. et al. Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nat. Commun. 9, 1251 (2018).","journal-title":"Nat. Commun."},{"key":"65456_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-immunol-101320-123742","volume":"40","author":"ML Matsumoto","year":"2022","unstructured":"Matsumoto, M. L. Molecular mechanisms of multimeric assembly of IgM and IgA. Annu. Rev. Immunol. 40, 221\u2013247 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"65456_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.it.2019.12.005","volume":"41","author":"E Michaud","year":"2020","unstructured":"Michaud, E., Mastrandrea, C., Rochereau, N. & Paul, S. Human secretory IgM: an elusive player in mucosal immunity. Trends Immunol. 41, 141\u2013156 (2020).","journal-title":"Trends Immunol."},{"key":"65456_CR39","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.4049\/jimmunol.162.6.3448","volume":"162","author":"V S\u00f8rensen","year":"1999","unstructured":"S\u00f8rensen, V., Sundvold, V., Michaelsen, T. E. & Sandlie, I. Polymerization of IgA and IgM: roles of Cys309\/Cys414 and the secretory tailpiece. J. Immunol. 162, 3448\u20133455 (1999).","journal-title":"J. Immunol."},{"key":"65456_CR40","doi-asserted-by":"publisher","first-page":"117741","DOI":"10.1016\/j.trac.2024.117741","volume":"176","author":"A Jug","year":"2024","unstructured":"Jug, A., Bratkovi\u010d, T. & Ila\u0161, J. Biolayer interferometry and its applications in drug discovery and development. TrAC Trends Anal. Chem. 176, 117741 (2024).","journal-title":"TrAC Trends Anal. Chem."},{"key":"65456_CR41","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20112655","volume":"209","author":"LE McCoy","year":"2012","unstructured":"McCoy, L. E. et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209, 1091\u20131103 (2012).","journal-title":"J. Exp. Med."},{"key":"65456_CR42","doi-asserted-by":"publisher","first-page":"042903","DOI":"10.1103\/PhysRevE.83.042903","volume":"83","author":"A Valleriani","year":"2011","unstructured":"Valleriani, A., Zhang, G., Nagar, A., Ignatova, Z. & Lipowsky, R. Length-dependent translation of messenger RNA by ribosomes. Phys. Rev. E 83, 042903 (2011).","journal-title":"Phys. Rev. E"},{"key":"65456_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0684.2009.00394.x","volume":"39","author":"LA Lugo-Roman","year":"2010","unstructured":"Lugo-Roman, L. A., Rico, P. J., Sturdivant, R., Burks, R. & Settle, T. L. Effects of serial anesthesia using ketamine or ketamine\/medetomidine on hematology and serum biochemistry values in rhesus macaques (Macaca mulatta). J. Med. Primatol. 39, 41\u201349 (2010).","journal-title":"J. Med. Primatol."},{"key":"65456_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/mi.2013.23","volume":"7","author":"C Moog","year":"2014","unstructured":"Moog, C. et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 7, 46\u201356 (2014).","journal-title":"Mucosal Immunol."},{"key":"65456_CR45","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","volume":"126","author":"RH Sayed","year":"2015","unstructured":"Sayed, R. H. et al. Natural history and outcome of light chain deposition disease. Blood 126, 2805\u20132810 (2015).","journal-title":"Blood"},{"key":"65456_CR46","unstructured":"Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies. Ann. Hematol. https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05911-9."},{"key":"65456_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/antib11040067","volume":"11","author":"E Narayanan","year":"2022","unstructured":"Narayanan, E. et al. Rational design and in vivo characterization of mRNA-encoded broadly neutralizing antibody combinations against HIV-1. Antibodies 11, 67 (2022).","journal-title":"Antibodies"},{"key":"65456_CR48","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler, C. R. et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 23, 815\u2013817 (2017).","journal-title":"Nat. Med."},{"key":"65456_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-S1-P23","volume":"7","author":"D Tudor","year":"2010","unstructured":"Tudor, D. et al. The immunoglobulin CH1 constant region modulates antigen binding affinity and functional activities of the broadly neutralizing 2F5 HIV specific antibody. Retrovirology 7, P23 (2010).","journal-title":"Retrovirology"},{"key":"65456_CR50","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.4049\/jimmunol.174.4.2132","volume":"174","author":"M Torres","year":"2005","unstructured":"Torres, M., May, R., Scharff, M. D. & Casadevall, A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J. Immunol. 174, 2132\u20132142 (2005).","journal-title":"J. Immunol."},{"key":"65456_CR51","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","volume":"10","author":"ME Sobieszczyk","year":"2023","unstructured":"Sobieszczyk, M. E. et al. Safety, tolerability, pharmacokinetics, and immunological activity of dual- and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: results of a phase 1 randomized trial. Lancet HIV 10, e653\u2013e662 (2023).","journal-title":"Lancet HIV"},{"key":"65456_CR52","doi-asserted-by":"publisher","first-page":"2032057","DOI":"10.1155\/2020\/2032057","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li, Y., Jin, L. & Chen, T. The effects of secretory IgA in the mucosal immune system. BioMed. Res. Int. 2020, 2032057 (2020).","journal-title":"BioMed. Res. Int."},{"key":"65456_CR53","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41586-021-03673-2","volume":"595","author":"Z Ku","year":"2021","unstructured":"Ku, Z. et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature 595, 718\u2013723 (2021).","journal-title":"Nature"},{"key":"65456_CR54","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3389\/fimmu.2019.01820","volume":"10","author":"ECY Law","year":"2019","unstructured":"Law, E. C. Y. et al. IgM antibodies can access cryptic antigens denied to IgG: hypothesis on novel binding mechanism. Front. Immunol. 10, 1820 (2019).","journal-title":"Front. Immunol."},{"key":"65456_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.it.2007.11.004","volume":"29","author":"M Torres","year":"2008","unstructured":"Torres, M. & Casadevall, A. The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol. 29, 91\u201397 (2008).","journal-title":"Trends Immunol."},{"key":"65456_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34090-2","volume":"13","author":"Q Chen","year":"2022","unstructured":"Chen, Q., Menon, R., Calder, L. J., Tolar, P. & Rosenthal, P. B. Cryomicroscopy reveals the structural basis for a flexible hinge motion in the immunoglobulin M pentamer. Nat. Commun. 13, 6314 (2022).","journal-title":"Nat. Commun."},{"key":"65456_CR57","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang, A. et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 23, 381\u2013396 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"65456_CR58","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/imcb.12324","volume":"98","author":"BS Goldberg","year":"2020","unstructured":"Goldberg, B. S. & Ackerman, M. E. Antibody-mediated complement activation in pathology and protection. Immunol. Cell Biol. 98, 305\u2013317 (2020).","journal-title":"Immunol. Cell Biol."},{"key":"65456_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01652-23","volume":"98","author":"D Bose","year":"2024","unstructured":"Bose, D. et al. SHIV-C109p5 NHP induces rapid disease progression in elderly macaques with extensive GI viral replication. J. Virol. 98, e0165223 (2024).","journal-title":"J. Virol."},{"key":"65456_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005431","volume":"12","author":"LJ Tartaglia","year":"2016","unstructured":"Tartaglia, L. J. et al. Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01_AE env sequences. PLoS Pathog. 12, e1005431 (2016).","journal-title":"PLoS Pathog."},{"key":"65456_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02267-18","volume":"93","author":"M Zhou","year":"2019","unstructured":"Zhou, M. et al. Adaptation of an R5 simian-human immunodeficiency virus encoding an HIV clade A envelope with or without ablation of adaptive host immunity: differential selection of viral mutants. J. Virol. 93, e02267-18 (2019).","journal-title":"J. Virol."},{"key":"65456_CR62","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1128\/JVI.00178-13","volume":"87","author":"W Ren","year":"2013","unstructured":"Ren, W. et al. Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques. J. Virol. 87, 6137\u20136149 (2013).","journal-title":"J. Virol."},{"key":"65456_CR63","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1021\/acsnano.1c10631","volume":"16","author":"JP Beyersdorf","year":"2022","unstructured":"Beyersdorf, J. P. et al. Robust, durable gene activation in vivo via mRNA-encoded activators. ACS Nano 16, 5660\u20135671 (2022).","journal-title":"ACS Nano"},{"key":"65456_CR64","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","volume":"39","author":"EL Blanchard","year":"2021","unstructured":"Blanchard, E. L. et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 39, 717\u2013726 (2021).","journal-title":"Nat. Biotechnol."},{"key":"65456_CR65","doi-asserted-by":"publisher","first-page":"2202771","DOI":"10.1002\/advs.202202771","volume":"9","author":"D Vanover","year":"2022","unstructured":"Vanover, D. et al. Nebulized mRNA-encoded antibodies protect hamsters from SARS-CoV-2 infection. Adv. Sci. 9, 2202771 (2022).","journal-title":"Adv. Sci."},{"key":"65456_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2010.05.003","volume":"359","author":"K Vorauer-Uhl","year":"2010","unstructured":"Vorauer-Uhl, K., Wallner, J., Lhota, G., Katinger, H. & Kunert, R. IgM characterization directly performed in crude culture supernatants by a new simple electrophoretic method. J. Immunol. Methods 359, 21\u201327 (2010).","journal-title":"J. Immunol. Methods"},{"key":"65456_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).","journal-title":"PLoS Pathog."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65456-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:05:59Z","timestamp":1764083159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65456-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65456"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65456-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10463"}}